DRUG · Unmapped registry intervention
BL-B01D1
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
NCT07641855
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Abiraterone
Normalized identity: abirateroneView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Olaparib
Normalized identity: olaparibView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2, PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Castration-resistant Prostate Cancerunresolved
Interventions
BL-B01D1DRUG
AbirateroneDRUG · verified · RxNorm: abiraterone
OlaparibDRUG · verified · RxNorm: olaparib
Sponsors & collaborators
Sichuan Baili Pharmaceutical Co., Ltd.lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07641855 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.